Skip to content
AwardedSVNGoods€450,000

Genomsko testiranje za načrtovanje zdravljenja zgodnjega raka dojke

Published
Published 11 December 2024
Deadline
Closed 24 January 2025

Overview

Genomska testa OncotypeDX in Mammaprint, sta v 3. fazi kliničnih študij (TailorX in Mindact) izkazala klinično uporabnost 1. stopnje pri adjuvantnem sistemskem zdravljenju z endokrino terapijo in brez kemoterapije. Na podlagi rezultatov sta oba testa vključena v glavne mednarodne klinične smernice. V kliničnih smernicah Nacionalne celovite mreže centrov za raka (NCCN) sta testa uvrščena v 1. stopnjo klinične uporabnosti. Glede na navedeno naročnik oddaja javno naročilo za predmet naročila št. JN-0040/2024 za »Genomsko testiranje za načrtovanje zdravljenja zgodnjega raka dojke«, v dveh sklopih in sicer: Sklop 1: test Oncotype DX® (Exact Sciences) Sklop 2: test Mammaprint® (Agendia) Ponudnik lahko predloži ponudbo za posamezen sklop ali oba sklopa.

Key details

Country
SVN
Status
Awarded
Category
Goods
Estimated value
€450,000
Procedure
Open
SME suitable
Yes
Published
11 December 2024
Deadline
Closed
Classification (CPV)
Pharmaceutical products

Award outcome

Awarded value
€465,000
Award date
3 April 2025
Contract period
— → 2 April 2026
Winners
  • DIAGENOMI, znanstvena raziskovalna in razvojna dejavnost, d.o.o.
  • Med Gen-Sol Kft

Contract ending soon? Skim tracks incumbents and flags recompetes early. Book a demo to set up alerts.

Notice history

Every published notice in this contracting process, newest first.

  1. Contract Award Notice

    17 July 2025

  2. Contract Notice

    15 January 2025

  3. Contract Notice

    11 December 2024

Contracting authority

Get the full picture

AI analysis, bid scoring, and expert strategy for this tender

Skim analyses every tender against your company profile and tells you whether to bid, how to win, and who you are up against.

See which competitors are winning the contracts you're chasing.

15-minute call. We'll pull the win data on your real pipeline and show you what Skim does with it.

Awarded: Genomsko testiranje za načrtovanje zdravljenja zgodnjega raka dojke — won by DIAGENOMI, znanstvena raziskovalna in razvojna dejavnost, d.o.o. +1 — Skim